Antifibrinolytics by Székely, Andrea & Lex, Dániel
5Heart, Lung and Vessels. 2014, Vol. 6
Antifibrinolytics have been increasingly used during operations as-
sociated with high risk of bleeding. New research and understand-
ing of coagulation and access to point of care coagulation monitors 
allow a goal-directed perioperative coagulation management strat-
egy. Certain drugs, such as aprotinin (1) and hydroxyethyl starch 
solutions, have been temporarily suspended from the market (2, 3) 
because of safety concerns.
Recent transfusion guidelines recommend (Class 1A) antifibrinolyt-
ics for routine administration in cardiac procedures if there are no 
contraindications (4).
Fibrinolysis is a physiological process where the activated plasmino-
gen removes excess fibrin and promotes better fibrin clot formation 
and wound healing. Tissue plasminogen activator (t-PA) and other 
activators of plasminogen are first line agents in lysis therapy. Inhib-
itors of this process act at the step where plasminogen is converted 
to plasmin, by reversely blocking the lysine binding sites of plasmin 
or by active inhibition of plasmin via serine protease inhibition. The 
drugs used for inhibition of fibrinolysis are the lysine analogues, 
tranexamic acid and ε-aminocaproic acid, and the serine protease 
inhibitor, aprotinin. Aprotinin also inhibits kallikrein and trypsin, 
and decreases the activation of neutrophils and platelets (5).
Inhibition of fibrinolysis reduces bleeding and blood transfusions in 
many types of surgery. Cardiopulmonary bypass (CPB) and cardio-
vascular surgery activate inflammatory pathways, coagulation cas-
cades, and fibrinolysis. Additionally, hemodilution and hypothermia 
during CPB also have detrimental effects on coagulation. However, 
one-third of off-pump coronary bypass patients receive blood prod-
ucts and this percentage might be reduced by the usage of antifi-
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brinolytics (6). The recently-described re-
gional hypercoagulable state which leads to 
thromboembolic events might also be pre-
vented by the usage of antifibrinolytics (7). 
While antifibrinolytics are useful drugs in 
the management of optimal coagulation, it 
is not a drug for all purposes. In elective sur-
gery, the first outpatient evaluation should 
ask about the type and combination of an-
tithrombotic agents, the presence of drug 
eluting stents, inherited or acquired coagu-
lation disorders or organ dysfunction, pres-
ence of anemia, and even religious consid-
erations. The interruption of long half-life 
anticoagulant and antiplatelet drugs and 
the bridging with short term agents for the 
perioperative period should be discussed. 
The surgeons should ensure meticulous 
haemostasis and apply blood-sparing surgi-
cal techniques. Topical administration of 
antifibrinolytics is becoming common, but 
according to the consensus statement from 
the International Society for Minimally 
Invasive Cardiothoracic Surgery (ISMICS) 
2011 it is not recommended (8). Anesthe-
siologists should optimize blood conserva-
tion and cell-salvage strategies, and proper 
administration and titration of pharmaco-
logical agents to avoid coagulopathy. Intra-
operative fluid management optimization 
to avoid hemodilution is also an important. 
Point-of-care instruments provide addition-
al information about the coagulation state 
(activated clotting time, thromboelastogra-
phy). These provide more detailed informa-
tion about the hemostatic system, support-
ing patient safety (9, 10). 
Aprotinin was considered the best pharma-
cological approach to blood conservation 
in cardiac surgery. As a result, the vast ma-
jority of studies on this subject used apro-
tinin and only few reports were available 
for the lysine analogues. In 2008, aprotinin 
was withdrawn from the market following 
the early release of the results of the Blood 
Conservation using Antifibrinolytics in a 
Randomized Trial (BART) study which 
found increased mortality associated with 
its use (11). An international consensus 
conference subsequently identified apro-
tinin as one of the few drugs that increases 
30-day mortality after cardiac surgery (12). 
More recently, the BART study data have 
been independently re-analyzed by the 
European Medicines Agency and Health 
Canada, with both agencies recommending 
a lifting of the suspension of aprotinin (13, 
14) suggesting that it can be used in non-
complex cardiac surgery. While the benefits 
of aprotinin would seem to be greater in 
more complex cardiac surgical procedures, 
the effect on mortality and morbidity in 
this high-risk patient group has not been 
defined by randomized controlled trials 
with sufficient statistical power. 
An updated re-analysis of the Cochrane 
Database has found no difference in mor-
tality when aprotinin was compared with 
placebo control (6). Similarly, there was no 
difference in mortality if aprotinin is com-
pared either to tranexamic acid or to epsi-
lon aminocaproic acid. However, the risk 
of death was higher in aprotinin-treated 
patients when compared with both lysine 
analogues, if the BART study data were in-
cluded, (relative risk 1,22; 95% confidence 
interval: 1.08-1.39) (6).
Tranexamic acid and ε-aminocaproic acid 
seem not to increase the occurrence of 
thromboembolic events, but few studies 
have included relevant endpoints in their 
design and so the evidence base is incom-
plete (15). The Aspirin and Tranexamic 
Acid for Coronary Artery Surgery (ATA-
CAS) trial is enrolling 4,600 cardiac surgi-
cal patients to definitively evaluate the risk 
of thrombotic complications in this setting 
(16). A retrospective study showed a two-
fold increase of convulsive seizures in pa-
tients undergoing open-heart surgery even 
after propensity score adjustment. Admin-
istration of tranexamic acid is not recom-
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mended in neonates and infants below 12 
months of age (17).
Recent guidelines state that ε-aminocaproic 
acid and tranexamic acid reduce exposure 
to allogenic blood transfusions in patients 
undergoing on-pump cardiac surgery. These 
agents are recommended to be used routine-
ly as part of the blood conservation strategy, 
especially in patients undergoing on-pump 
cardiac surgery (Class I, Level A) and also 
in high-risk patients undergoing off-pump 
coronary artery bypass (OPCAB) surgery 
(Class I, Level A). It is important not to ex-
ceed maximum tranexamic acid total dos-
ages (50-100 mg/kg) because of potential 
neurotoxicity in the elderly and open-heart 
procedures (Class IIb, Level C) (8).
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